

**Translation of Immediate Report Filed by Elron on November 10, 2025 with the Israeli
Securities Authority**

Re: Nitinotes - Response to a Media Publication

Further to the information provided in Section 23 in Part A - Description of Corporation's Business in Elron's annual report for 2024, published on March 30, 2025, regarding Nitinotes' intention to complete the submission of its application for CE marketing approval in Europe for the *Endozip™* system- an endoscopic system for automatic gastric suturing aimed at reducing stomach volume and gastric motility for the treatment of obesity - and in light of the article published yesterday in *Calcalist*, Elron hereby updates that on November 3, 2025, Nitinotes received CE marketing approval in Europe for the *Endozip™* product.

Elron holds approximately 14% of Nitinotes' share capital (12% on a fully diluted basis). The investment in Nitinotes is accounted for as a financial asset measured at fair value through profit or loss, and as of June 30, 2025, was valued at approximately USD 2 million in Elron's Financial Statements. This value will be reassessed in Elron's 2025 Annual Financial Statements with the assistance of an external appraiser.

Date and time the corporation first became aware of the event or matter:
November 9, 2025, at 13:59.